Calcimimetic Agents

"Calcimimetic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR) in the PARATHYROID GLANDS and other tissues. They lower the threshold for CaSR activation by extracellular calcium ions and diminish PARATHYROID HORMONE (PTH) release from parathyroid cells.

Descriptor ID

D057966

MeSH Number(s)

D06.347.230

D27.505.696.399.450.230

Concept/Terms

Calcimimetic Agents

Below are MeSH descriptors whose meaning is more general than "Calcimimetic Agents".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormone Antagonists [D06.347]
Calcimimetic Agents [D06.347.230]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hormones, Hormone Substitutes, and Hormone Antagonists [D27.505.696.399]
Hormone Antagonists [D27.505.696.399.450]
Calcimimetic Agents [D27.505.696.399.450.230]

Below are MeSH descriptors whose meaning is related to "Calcimimetic Agents".

Below are MeSH descriptors whose meaning is more specific than "Calcimimetic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Calcimimetic Agents" by people in Harvard Catalyst Profiles by year, and whether "Calcimimetic Agents" was a major or minor topic of these publication.

Bar chart showing 9 publications over 8 distinct years, with a maximum of 2 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2011	0	1	1
2013	0	2	2
2014	0	1	1
2016	1	0	1
2018	1	0	1
2019	1	0	1
2020	1	0	1
2021	1	0	1

Below are the most recent publications written about "Calcimimetic Agents" by people in Profiles.

Decreasing Surgical Management of Secondary Hyperparathyroidism in the United States. J Surg Res. 2021 08; 264:444-453.

View in: PubMed
Surgical outcomes of parathyroidectomy for secondary hyperparathyroidism resistant to calcimimetic treatment: A retrospective single-center cohort study. Ther Apher Dial. 2021 Apr; 25(2):188-196.

View in: PubMed
Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int. 2019 05; 95(5):1064-1078.

View in: PubMed
Vitamin D and Calcimimetics in Cardiovascular Disease. Semin Nephrol. 2018 05; 38(3):251-266.

View in: PubMed
Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int. 2017 03; 91(3):658-670.

View in: PubMed
Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study. PLoS One. 2016; 11(10):e0164865.

View in: PubMed
Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis. Hemodial Int. 2016 10; 20(4):589-600.

View in: PubMed
Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 2014 Dec; 86(6):1106-15.

View in: PubMed
What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? Curr Opin Nephrol Hypertens. 2013 Nov; 22(6):651-5.

View in: PubMed
Dialysis: Effect of cinacalcet on survival--the saga continues. Nat Rev Nephrol. 2013 Aug; 9(8):435-6.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Kidney Int
PLoS One
Nat Rev Nephrol
J Surg Res
Hemodial Int
Expert Opin Pharmacother
Expert Opin Biol Ther
Br J Pharmacol
Ann Surg
Am J Nephrol